Valganciclovir is an antiviral medication. Here are the essentials:
- What it is: An oral prodrug that is converted in the body to ganciclovir, which inhibits viral DNA replication.
- What it’s used for:
- Prevention of CMV (cytomegalovirus) disease in high-risk renal or other solid organ transplant recipients.
- Treatment of CMV infection/disease (including CMV retinitis) in adults, including CMV retinitis in people with AIDS.
- Suppressive therapy to prevent CMV retinitis reactivation in some patients.
- How it’s given: Taken by mouth with food. Dosing depends on the indication and renal function. Common adult regimens include:
- Prophylaxis (post-transplant): often around 900 mg once daily.
- Treatment of CMV disease or CMV retinitis (induction): commonly 900 mg twice daily, then may be reduced to once daily for maintenance.
- Dosing must be adjusted for kidney function (renal impairment requires dose modification). Exact adjustments should follow the product labeling or your clinician’s instructions.
- Important safety notes:
- Common side effects: bone marrow suppression (neutropenia, anemia, thrombocytopenia), nausea, diarrhea, vomiting, lowered white blood cell count, liver test abnormalities.
- Serious risks: severe neutropenia/infections, hepatotoxicity; potential for kidney function impact.
- Pregnancy and fertility: valganciclovir is teratogenic. It should be avoided in pregnancy. Women of childbearing potential should use effective contraception during treatment and for a period afterward. Discuss contraception if you’re of childbearing potential.
- Breastfeeding: generally advised not to breastfeed during treatment.
- Drug interactions and cautions:
- Increases in bone marrow suppression can occur when used with other myelosuppressive drugs (e.g., zidovudine/AZT, mycophenolate, certain chemotherapies).
- Monitor blood counts, liver and kidney function, and CMV viral load if you’re treating active CMV disease.
- Don’t use without medical supervision if you have significant kidney disease or a low blood cell count.
- What to discuss with a healthcare provider:
- Your exact indication (prevention after transplant vs treatment vs CMV retinitis).
- Kidney function (creatinine clearance) and any other meds you’re taking.
- Pregnancy/breastfeeding status or plans.
- Any history of marrow problems, liver disease, or frequent infections.
If you have a specific scenario (e.g., kidney function, post-transplant prophylaxis, CMV retinitis in AIDS, or questions about side effects or interactions), tell me and I can tailor the info or provide example dosing and monitoring details.